Toronto, Ontario--(Newsfile Corp. - May 23, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the Company's wholly-owned subsidiary, Securedose Synthetics Inc. ("SecureDose") has signed an... Read More

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one... Read More

Toronto, Ontario--(Newsfile Corp. - May 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs is pleased to provide a Corporate update from CEO, Robert Steen, to outline its forward strategic and tactical plan to move its... Read More

Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board of directors, subject to... Read More

Toronto, Ontario--(Newsfile Corp. - May 1, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that Sairiyo Therapeutics Inc. ("Sairiyo"), a company that is fifty-one... Read More

Victoria's Chiral Labs to lead development of novel cocaine manufacturing process Toronto, Ontario--(Newsfile Corp. - April 16, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that the... Read More

Toronto, Ontario--(Newsfile Corp. - March 13, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC PINK: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines, and previously approved drugs, is pleased to announce that it has initiated work on a project to develop a novel manufacturing method for the... Read More

Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that current board member Dr. David Kideckel has been appointed Chairman... Read More

Company to pursue regulatory filing for Phase I/II clinical study Toronto, Ontario--(Newsfile Corp. - February 14, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to provide an... Read More

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), today announced that it has entered into (i) a marketing and distribution services agreement (the " OTB Agreement ") with an arm's length marketing firm, Outside The Box Capital Inc. (" OTBC ") to provide marketing services, including digital marketing services through various social... Read More

Toronto, Ontario--(Newsfile Corp. - February 8, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), is pleased to announce the closing of its previously announced non-brokered private placement raising total gross proceeds of $326,000 (the " Offering "). Pursuant to the Offering the Company issued 6,520,000 units (" Units ") at a purchase price of $0.05 per Unit for aggregate gross... Read More

Toronto, Ontario--(Newsfile Corp. - October 20, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), announced today that it will be proceeding with the consolidation of its common shares (the " Common Shares ") on the basis of seven (7) pre consolidated Common Shares into one (1) post consolidated Common Share (the " Share Consolidation "). The effective date for the Share Consolidation... Read More

Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director of the Company at the upcoming annual and special meeting of the Company's shareholders to be held on October 13, 2023 at 10:00 a.m. (Toronto... Read More

Toronto, Ontario--(Newsfile Corp. - September 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), is pleased to provide an update on the development activities of the Company's patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infectious disease. The technical transfer and development activities with... Read More

Toronto, Ontario--(Newsfile Corp. - September 6, 2023) - PharmaDrug Inc . (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), announced today the appointment of Robert J. Steen as Chief Executive Officer (CEO) and Chairman of the Board of Directors. Robert will replace Daniel Cohen, who will continue on in an advisory capacity to ensure a proper transition and steady state progress in the cepharanthine program.... Read More

Toronto, Ontario--(Newsfile Corp. - July 18, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), announced today that it has reached an agreement yesterday with PharmaTher Inc. (" PharmaTher "), a wholly-owned subsidiary of PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF), pursuant to which PharmaTher will subscribe for 144,117,647 common shares of PharmaDrug's subsidiary Sairiyo... Read More

Toronto, Ontario--(Newsfile Corp. - July 5, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), announced today that it has reached an agreement with the holders of $650,000 principal amount of the Company's convertible debentures to terminate a general security agreement granted by the Company's wholly-owned subsidiary Sairiyo Therapeutics Inc. (" Sairiyo "). As consideration for agreeing... Read More

Toronto, Ontario--(Newsfile Corp. - May 23, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), is announcing that it has appointed David Posner to its Advisory Committee and as a consultant with a mandate for strategic initiatives and corporate restructuring. Daniel Cohen, Chairman and CEO of PharmaDrug commented, "We are extremely excited to bring David Posner on as an advisor. David has... Read More

Toronto, Ontario--(Newsfile Corp. - May 8, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), is announcing that the Ontario Securities Commission has issued a "failure to file" cease trade order in respect of the Company's securities under Multilateral Instrument 11-103 Failure-to- File Cease Trade Orders in Multiple Jurisdictions (the "CTO"). The CTO was issued as a result of the Company's... Read More

Toronto, Ontario--(Newsfile Corp. - April 14, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $100,000 through the sale of debenture units ("... Read More

PharmaDrug is positioning to become a leader of DMT-based therapeutics for ocular disease and neuropsychiatric conditions Toronto, Ontario--(Newsfile Corp. - February 22, 2023) - PharmaDrug Inc . (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to... Read More

Toronto, Ontario--(Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company intends to pursue a first-in-human study of its lead development candidate, PD-001, enteric coated... Read More

Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has completed filing a PCT (Patent Cooperation Treaty) application for its lead drug,... Read More

Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance Optimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND filing and clinical requirements PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the... Read More

PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University in support of forthcoming (Q4, 2022) FDA IND Application for a Phase 1 clinical study to investigate persistent effects of DMT PharmaDrug extends contract with... Read More

Completes qualification of all necessary analytical methodologies to support production of Cepharanthine-2HCL drug substance Clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance scheduled for delivery in second half of September 2022 Genvion Corporation formally engaged to conduct ICH-compliant stability, forced degradation and drug product manufacturing in support of IND filing and clinical requirements... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" Pharmadrug " or the " Company "), is pleased to announce that it has closed the previously announced (see press release dated May 31, 2022) sale of all of the issued and outstanding securities of Pharmadrug Production GmbH (" Pharmadrug GmbH ") to Khiron Life Sciences Corp. (TSXV: KHRN) (" Khiron "). Pharmadrug GmbH, is a German medical cannabis distributor, with a Schedule I... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally-derived approved drugs, is pleased to announce that it has raised $650,000 through the sale of debenture units (" Units "). Each unit is comprised of a $1,000 principal... Read More

Results show that oral cepharanthine plus paclitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 28, the final day of dosing compared to paclitaxel alone (p=0.0049) Dose range finding demonstrates that oral cepharanthine-alone was well tolerated in the current in vivo study PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), is pleased to announce that it has entered into an agreement on May 31, 2022 with Khiron Life Sciences Corp. (TSXV: KHRN) (" Khiron ") to sell all of the outstanding securities of Pharmadrug Production GmbH, (" Pharmadrug GMBH ") the Company's wholly-owned German subsidiary, a medical cannabis distributor, with a Schedule I European Union... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the closing of the first tranche (the " First Tranche ") of a non-brokered private placement (the " Offering ") of... Read More

Selection of lead candidate from initial short-list of 6 DMT-analogues Lead candidate displays superior potency in two in vitro bioassays on two relevant human cell types In vitro safety and biocompatibility testing using drug-loaded medical device demonstrates tolerability at doses anticipated to be within therapeutic range Results to be leveraged by filing of Provisional Patent detailing a novel approach to treating... Read More

Provisional patent filed (April 14, 2022) to support use of PD-001 plus cabazitaxel for primary, metastatic and chemotherapy-resistant prostate cancer Final study results show that oral cepharanthine (PD-001) plus cabazitaxel combination therapy significantly reduced tumor volume and increased tumor growth inhibition Dose range finding demonstrates that oral cepharanthine-alone was well tolerated Addition of PD-001 to... Read More

Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range Current results provide Company with refined focus for two candidate molecules PharmaDrug Inc. (CSE:... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to provide an update on multiple activities currently underway which support the Company's 'pipeline-in-a-pill' approach in the... Read More

Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of dosing Dose range findings demonstrate that oral cepharanthine-alone was well tolerated in the current in vivo study Results for oral cepharanthine plus cabazitaxel will be used to support PharmaDrug's recently submitted provisional patent... Read More

PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug's candidate DMT-analogue molecules into next phase of potency/kinetics study Terasaki Institute initiates fabrication of novel medical device designed to deliver PharmaDrug's lead candidate to glaucoma patients PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company's Chairman and CEO Daniel Cohen will be presenting at Wall Street Reporter's "Next Super Stock"... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that it has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program. As... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that Mr. Robert Schwartz has resigned from the board of directors of the Company (the " Board "), and the Board has accepted his... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, pleased to announce the addition of Dr. Cindy Hutnik to its scientific and clinical advisory board. Dr. Hutnik will assist the Company in its... Read More

Established alignment with FDA on the path forward for the development of PD-001, a patented enteric-coated formulation of cepharanthine, towards clinical studies for mild-moderate COVID-19 infection Meeting response validates CMC package for PD-001 as an oral anti-viral to treat COVID-19 infection PharmaDrug intends to pursue FDA Expedited Programs, such as Breakthrough Designation pending future clinical study data for... Read More

Results of the 4 cancer types where cepharanthine provides exceptional potency and/or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy provides support for next development stage Advancing Cepharanthine (PD-001) to IND-enabling efficacy studies to support potential FDA clinical studies in... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Terasaki Institute for Biomedical Innovation (TIBI) has received and will immediately commence in vitro... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its 100% owned cannabis and controlled substance distributor Pharmadrug Production GmbH (" Pharmadrug... Read More

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has qualified for trading on the OTCQB Venture Market (the "OTCQB") operated by the OTC Markets Group Inc. The... Read More

Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment options Identified 4 cancer types where cepharanthine provides additive or synergistic inhibitory effects when combined with standard of care (SoC) chemotherapy Continued focus on esophageal cancer as most highly responsive cancer examined FDA IND-enabling animal efficacy studies planned for Q4, 2021... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has been granted a Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division is launching its own premium blend of functional mushrooms. MycoWe℞ Infinite will... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that David Kideckel will be joining the board effective immediately. David joins PharmaDrug after nearly 20... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical Trial Agreement with The Johns Hopkins University (JHU) to conduct... Read More

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that Harbourside CPA, LLP (the " Successor Auditor ") has been appointed as the Company's auditor effective as of... Read More

Unlocking the potential of psychedelics, including DMT, and other tryptamines to treat the significant unmet medical needs of glaucoma patients Partnering with world-renowned research institution brings validated drug delivery expertise in novel, controlled drug-release technologies PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research,... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it will change its ticker symbol from " BUZZ " to " PHRX ". The Company expects the symbol change to take... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce interim positive results from its ongoing preclinical study evaluating the Company's patented enteric-coated... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that MNP LLP (the " Former Auditor ") has resigned as the Company's auditors, with the resignation being effective as... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has initiated preparation of a Pre-Investigational New Drug Application (pre-IND) for its... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a Slim Winkel branded online retail platform in The Netherlands and... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a Slim Winkel branded online retail platform in the U.S. that will... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a supply agreement (the " Supply Agreement ") with an emerging Eurozone cannabis... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into an employment agreement with Dr. Paul Van Slyke and promoted him to Chief Scientific... Read More

PharmaDrug Inc . (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into an agreement with Southwest Research Institute® ("SwRI®"), to initiate... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a sponsored research agreement with the University of Michigan, under the... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), will hold its Annual General Meeting (" AGM " or " Meeting ") on March 25, 2021 at 10:00AM Eastern Standard Time at its corporate office, Suite 2905 - 77 King Street West, Toronto. The call-in number for the Meeting is 1-855-473-1059 and the access # 0091269. In light of the ongoing COVID-19 situation, the Company strongly encourages... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sairiyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") wholly-owned subsidiary, Sariyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned gastric... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that is has appointed world-renowned chemist and neuroscientist Dr. Steven A. Barker, Ph.D. to the Company's... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") announces the grant of stock options to directors, officers and consultants to purchase 5,200,000 common shares of the Company, exercisable at $0.085 per share at any time on or before February 4, 2026. The grants are subject to the terms of the Company's stock option plan. In accordance with regulatory requirements, any shares issued pursuant... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (" PharmaDrug " or the " Company ") has entered into a supply agreement (the " Supply Agreement ") on January 4, 2021, with a Canadian based multinational cannabis company for EU-GMP certified medical cannabis. The supply is already registered and approved for sale in the German market. Pursuant to the Supply Agreement, the Company's licensed German distributor, Pharmadrug... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has completed the previously announced (see press releases dated January 12, 2021 and January 25, 2021) acquisition of Sairiyo... Read More

PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (" PharmaDrug " or the " Company "), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has entered into the definitive agreement in respect of the previously announced (see press release dated January 12, 2021)... Read More